134 related articles for article (PubMed ID: 37160667)
21. Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
Migliore M; Habrant D; Sasso O; Albani C; Bertozzi SM; Armirotti A; Piomelli D; Scarpelli R
Eur J Med Chem; 2016 Feb; 109():216-37. PubMed ID: 26774927
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
23. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A
J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.
Bonaterra GA; Kelber O; Weiser D; Kinscherf R
Phytomedicine; 2013 Jun; 20(8-9):691-8. PubMed ID: 23535188
[TBL] [Abstract][Full Text] [Related]
25. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
[TBL] [Abstract][Full Text] [Related]
26. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks.
Moran EM
J Environ Pathol Toxicol Oncol; 2002; 21(2):193-201. PubMed ID: 12086406
[TBL] [Abstract][Full Text] [Related]
27. Outstanding Anti-inflammatory Potential of Selected Asteraceae Species through the Potent Dual Inhibition of Cyclooxygenase-1 and 5-Lipoxygenase.
Chagas-Paula DA; Oliveira TB; Faleiro DP; Oliveira RB; Costa FB
Planta Med; 2015 Sep; 81(14):1296-307. PubMed ID: 26227502
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
Charlier C; Michaux C
Eur J Med Chem; 2003; 38(7-8):645-59. PubMed ID: 12932896
[TBL] [Abstract][Full Text] [Related]
29. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study.
El-Miligy MMM; Hazzaa AA; El-Messmary H; Nassra RA; El-Hawash SAM
Bioorg Chem; 2017 Jun; 72():102-115. PubMed ID: 28390993
[TBL] [Abstract][Full Text] [Related]
30. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
31. New benzothiophene derivatives as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study.
El-Miligy MM; Hazzaa AA; El-Messmary H; Nassra RA; El-Hawash SA
Future Med Chem; 2017 Apr; 9(5):443-468. PubMed ID: 28362117
[TBL] [Abstract][Full Text] [Related]
32. In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
Ottanà R; Carotti S; Maccari R; Landini I; Chiricosta G; Caciagli B; Vigorita MG; Mini E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3930-3. PubMed ID: 15993594
[TBL] [Abstract][Full Text] [Related]
33. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tebufelone distribution in rat blood plasma and inflamed and noninflamed tissues following peroral and intravenous administration.
Doyle MJ; Eichhold TH; Loomans ME; Farmer RW; Kelm GR
J Pharm Sci; 1993 Aug; 82(8):847-50. PubMed ID: 8377126
[TBL] [Abstract][Full Text] [Related]
36. Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro.
Guo W; Nie L; Wu D; Wise ML; Collins FW; Meydani SN; Meydani M
Nutr Cancer; 2010; 62(8):1007-16. PubMed ID: 21058188
[TBL] [Abstract][Full Text] [Related]
37. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
Mandal P; Kundu BK; Vyas K; Sabu V; Helen A; Dhankhar SS; Nagaraja CM; Bhattacherjee D; Bhabak KP; Mukhopadhyay S
Dalton Trans; 2018 Jan; 47(2):517-527. PubMed ID: 29235601
[TBL] [Abstract][Full Text] [Related]
38. Conjugation of 4-aminosalicylate with thiazolinones afforded non-cytotoxic potent in vitro and in vivo anti-inflammatory hybrids.
Abdu-Allah HHM; Abdelmoez AAB; Tarazi H; El-Shorbagi AA; El-Awady R
Bioorg Chem; 2020 Jan; 94():103378. PubMed ID: 31677858
[TBL] [Abstract][Full Text] [Related]
39. Potent androgen antagonists based on carborane as a hydrophobic core structure.
Fujii S; Goto T; Ohta K; Hashimoto Y; Suzuki T; Ohta S; Endo Y
J Med Chem; 2005 Jul; 48(14):4654-62. PubMed ID: 16000001
[TBL] [Abstract][Full Text] [Related]
40. Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors.
Kramer JB; Capiris T; Sircar JC; Connor DT; Bornemeier DA; Dyer RD; Kuipers PJ; Kennedy JA; Wright CD; Okonkwo GC
Bioorg Med Chem; 1995 Apr; 3(4):403-10. PubMed ID: 8581424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
